Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Lin Shen, Director
Beijing Cancer Hospital, China
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Beijing Cancer Hospital
Beijing, Beijing Municipality, China
- Chongqing Cancer Hospital
Chongqing, Chengdu, China
- Jilin Cancer Hospital
Changchun, Jilin, China
- Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, China
- West China Second University Hosital, Sichuan University
Chengdu, Sichuan, China
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 1 Jul 2022
- Primary completion
- 25 Jun 2024
- Completion
- 18 Jul 2024
- Last update posted
- 17 Nov 2025
- Registered enrollment
- 22
- Registry id
- NCT05383482
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.